Through its new MiniMed 670G performance guarantee program, Medtronic said it will provide flat-fee reimbursements up to $25,000 per pump over four years of qualifying diabetes-related inpatient hospitalization and emergency room admissions for eligible in-network patients in the United States.
News & Features
Abbott Laboratories reported a strong second quarter overall, but in medical devices, the company appears to be losing share in cardiac rhythm management and neuromodulation. Could Abbott's loss in these markets be Medtronic or Boston Scientific's gain?
Could force sensors provide the necessary human-like touchpoints for smart-connected medical devices?
Though they are best known as a popular candy, gummy bears have found a different use as a transport for microelectrodes with increased biocompatibility, thanks to researchers from the Technical University of Munich . A team there, collaborating with researchers at Germany’s Forschungszentrum...
Baxter said it is evaluating other potential locations, including contract manufacturers, to support its supply needs if necessary.
NuVasive said the next evolution of its Reline system allows for greater procedural flexibility while enhancing visibility and access.
The company asked the court to dismiss a negligence case involving St. Jude Medical's Riata ST lead, but a federal judge denied the motion, allowing the case to proceed.
Endologix promoted from within to fill the CEO seat. Will this strategy help the struggling EVAR company up its game?
Angiodynamics CEO Jim Clemmer assures investors that the company is ready and able to execute M&A opportunities, either in terms of divestitures or acquisitions.
A new study offers more evidence that single-use bronchoscopes could be a better alternative to reusable devices.
MD+DI News Editor Amanda Pedersen talks about recent M&A trends in medtech and the attributes that make companies stand out as potential acquisition targets.
Researchers in the UK have achieved the first 3D printing of human corneas that can potentially be used in replacement surgeries. In doing so, they have paved the way for an unlimited and easy-to-fabricate supply of new corneas to patients that need them, they said. Key to the achievement by...
The San Francisco, CA-based company has raised $26.6 million in a series C round to help further commercialize its Accuryn Monitoring System.